Merck enlisted Daktari Diagnostics to help it break into the hepatitis C market and execute its strategy of appealing to unserved niche patients, such as hep C patients with dialysis and rare genotype 4 of the virus.
LONDON-- Late last month, partners Eli Lilly and Boehringer Ingelheim announced that their SGLT2 diabetes med, Jardiance, had gone where no others had gone before. While its rivals had always either increased the risk of cardiovascular events or, at best, had no effect, the newcomer showed it could actually lower the risk of heart attack, stroke and death from cardiovascular causes.
As if last week's Jardiance news wasn't enough to worry makers of DPP-4 diabetes drugs, the FDA has now issued a warning that the class of meds might cause "severe and disabling" joint pain.
The good news keeps rolling in for Merck when it comes to the cardiovascular safety of its DPP-4 inhibitor, Januvia. According to a new analysis of the TECOS trial, patients with Type 2 diabetes and cardiovascular disease--even those with a history of heart failure--can take the drug without an increased risk of CV complications.
A packaging problem has led Merck to recall 276,000 bottles of a cancer med because the child-proof feature can fail, allowing children to get their hands on the chemo drug.
Australia's Therapeutic Good Administration has registered mAb biosimilar Inflectra (infliximab) from Hospira, the company said in a press release, noting it sets the stage for reimbursement under the country's Pharmaceutical Benefits Scheme.
Merck & Co.'s plant in Pennsylvania has been impacted by the drugmaker's drastic job cuts in the last 5 years, losing hundreds of manufacturing jobs. Now, in an email exchange made public by one of the unions there, a labor official has lashed out at CEO Ken Frazier, saying workers are now forced to work 16-hours shifts, the fatigue from which puts themselves and others in danger.
Merck & Co.'s CEO Kenneth Frazier thought he was doing a good thing when he announced that employees would get an extra day off in appreciation for their hard work. But the fact that union employees are not getting the extra time at the Labor Day holiday has led one union official to publicly lash out at Merck and Frazier.
Merck's Januvia has seen its fair share of competition from generics makers and other diabetes challengers. But now, it could face a new rival on the scene--and it's a device.
Merck & Co. has encountered a few roadblocks in recent years with its diabetes drug, Januvia as safety concerns took a bite out of sales. The company has worked hard to reverse this trend, and recently unveiled data on heart safety could do its part. But now Merck could be facing another threat, and not from a regulator or competing drugmaker--but a devicemaker.